Genetics of 4R-Tauopathies: Cross-Disease Comparison

Genetics of 4R-Tauopathies: Cross-Disease Comparison

The 4R-tauopathies are a family of neurodegenerative disorders characterized by the preferential accumulation of four-repeat (4R) tau isoforms in the brain. This page provides a comprehensive comparison of the genetic architecture across the major 4R-tauopathies: Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), Argyrophilic Grain Disease (AGD), Globular Glial Tauopathy (GGT), and Frontotemporal Dementia with Parkinsonism linked to Chromosome 17 (FTDP-17).

Overview

The 4R-tauopathies share the common feature of tau protein pathology consisting of 4R-tau isoforms. However, they differ in their genetic risk profiles, with some shared genetic factors and disease-specific mutations. Understanding these genetic similarities and differences provides insight into disease mechanisms and potential therapeutic targets.

Shared Genetic Architecture

MAPT Gene and H1 Haplotype

The [MAPT gene](/genes/mapt) (Microtubule-Associated Protein Tau) located on chromosome 17q21.31 is central to all 4R-tauopathies. The H1 haplotype of MAPT is the major genetic risk factor for sporadic forms of PSP, CBD, and to a lesser extent, AGD[@conrad2007][@rizzu1999].

Genetics of 4R-Tauopathies: Cross-Disease Comparison

The 4R-tauopathies are a family of neurodegenerative disorders characterized by the preferential accumulation of four-repeat (4R) tau isoforms in the brain. This page provides a comprehensive comparison of the genetic architecture across the major 4R-tauopathies: Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), Argyrophilic Grain Disease (AGD), Globular Glial Tauopathy (GGT), and Frontotemporal Dementia with Parkinsonism linked to Chromosome 17 (FTDP-17).

Overview

The 4R-tauopathies share the common feature of tau protein pathology consisting of 4R-tau isoforms. However, they differ in their genetic risk profiles, with some shared genetic factors and disease-specific mutations. Understanding these genetic similarities and differences provides insight into disease mechanisms and potential therapeutic targets.

Shared Genetic Architecture

MAPT Gene and H1 Haplotype

The [MAPT gene](/genes/mapt) (Microtubule-Associated Protein Tau) located on chromosome 17q21.31 is central to all 4R-tauopathies. The H1 haplotype of MAPT is the major genetic risk factor for sporadic forms of PSP, CBD, and to a lesser extent, AGD[@conrad2007][@rizzu1999].

• H1 Haplotype: The H1 haplotype spans the entire MAPT gene and is associated with increased expression of 4R-tau isoforms. Individuals homozygous for H1 have approximately 4-5x increased risk for PSP and CBD[@pittman2005].
• H2 Haplotype: The H2 haplotype is protective and is in linkage disequilibrium with the inversion polymorphism that reduces 4R-tau expression.

Disease-Specific Genetic Profiles

Progressive Supranuclear Palsy (PSP)

PSP is the prototypical 4R-tauopathy with the strongest genetic association with MAPT.

| Gene | Variant | Type | Risk/Effect |
|------|---------|------|-------------|
| MAPT | H1/H1 genotype | Risk | OR ≈ 5.5-7.8[@hoglinger2011] |
| MAPT | p.A152T | Risk | OR ≈ 2.3[@coppola2012] |
| MAPT | p.V363I | Protective | Reduces risk[@zhou2022] |
| STUB1 | Various | Risk | Increases susceptibility[@shin2018] |
| MOBP | rs1768208 | Risk | OR ≈ 1.5[@ferrari2018] |
| EIF2AK3 | rs7531528 | Risk | OR ≈ 1.4[@chen2020] |

PSP is predominantly sporadic, with only 5-10% of cases showing familial aggregation. The H1 haplotype accounts for the majority of genetic risk in sporadic PSP.

Corticobasal Degeneration (CBD)

CBD shares significant genetic overlap with PSP, particularly the MAPT H1 haplotype.

| Gene | Variant | Type | Effect |
|------|---------|------|--------|
| MAPT | H1/H1 genotype | Risk | OR ≈ 4.0[@litvan2017] |
| MAPT | Various mutations | Familial | 10% of cases |
| GRN | Null mutations | Risk | 5-10% of familial cases[@rascovsky2007] |
| LRRK2 | p.G2019S | Risk | Associated with parkinsonian features[@wadia2012] |
| CBD | 17q21.31 region | Risk | Shared with PSP |

CBD shows greater clinical and genetic heterogeneity than PSP, with approximately 10-20% of cases having a family history.

Argyrophilic Grain Disease (AGD)

AGD has the weakest genetic association with MAPT among the 4R-tauopathies.

| Gene | Variant | Population | Effect |
|------|---------|------------|--------|
| MAPT | H1 haplotype | All | Weaker association than PSP/CBD[@tol2015] |
| SVIL | rs2413229 | Japanese | Novel risk locus[@genomewide2025] |
| DAPK2 | Transcriptome | Japanese | Candidate causal gene |

A 2025 GWAS in Japanese populations identified SVIL (supervillin) as a novel risk locus, highlighting population-specific genetic architecture[@genomewide2025].

Globular Glial Tauopathy (GGT)

GGT is the rarest 4R-tauopathy with limited genetic data.

• MAPT: Most cases are sporadic with H1 haplotype association
• Chromosome 17q21.31: Region linked to FTDP-17 shows overlap
• Familial cases: Rare but reported with MAPT mutations

Frontotemporal Dementia with Parkinsonism-17 (FTDP-17)

FTDP-17 is distinct from other 4R-tauopathies as it is primarily caused by dominant MAPT mutations.

| Mutation | Location | Effect |
|----------|-----------|--------|
| P301L | Exon 10 | Most common, ~40% of families[@hutton2000] |
| P301S | Exon 10 | Early onset |
| G389R | Exon 12 | Variable expressivity |
| R406W | Exon 13 | Late onset, tauopathy |

Over 40 pathogenic MAPT mutations have been identified in FTDP-17 families. These mutations disrupt tau-microtubule binding, promote tau aggregation, and alter the 3R/4R isoform ratio[@ghetti2015].

Sporadic vs Familial Patterns

| Disease | Sporadic % | Familial % | Key Genes |
|---------|------------|------------|-----------|
| PSP | 90-95% | 5-10% | MAPT (H1) |
| CBD | 80-90% | 10-20% | MAPT, GRN, LRRK2 |
| AGD | ~95% | ~5% | MAPT (weak), SVIL |
| GGT | ~95% | ~5% | MAPT |
| FTDP-17 | <5% | >95% | MAPT (mutations) |

The gradient from nearly all sporadic (PSP, AGD) to nearly all familial (FTDP-17) reflects the underlying genetic architecture. FTDP-17 is unique as a monogenic tauopathy caused by specific MAPT mutations.

Genome-Wide Association Studies (GWAS)

PSP GWAS Findings

Major GWAS have identified multiple risk loci for PSP[@hoglinger2021]:

• MAPT (17q21.31): Strongest signal, H1 haplotype
• MOBP (3q22.1): Myelin-associated oligodendrocyte protein
• STUB1 (16p13.3): CHIP protein, involved in protein quality control
• EIF2AK3 (10p14): Endoplasmic reticulum stress response
• SLCO1A2 (15q26): Organic anion transporter

CBD GWAS Findings

CBD GWAS show significant overlap with PSP:

• MAPT H1: Primary risk factor
• GRN: Progranulin gene, shared with FTLD
• APOE: Apolipoprotein E, modifier of age at onset

AGD GWAS Findings

• SVIL (10p12): Novel locus identified in Japanese cohort[@genomewide2025]
• MAPT: Weak association
• DAPK2: Candidate causal gene from transcriptome analysis

Comparative Analysis

Key Insights

Therapeutic Implications

Understanding the shared and unique genetic architecture of 4R-tauopathies has important therapeutic implications:

See Also

• [MAPT gene](/genes/mapt)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References